Pompe Disease Pipeline Insights

DelveInsight’s, “Pompe Disease Pipeline Insight, 2026” report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Pompe Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pompe Disease Understanding

Pompe Disease Overview

Pompe disease, also known as glycogen storage disease type II (GSD II) or acid maltase deficiency (AMD), is a rare inherited disorder caused by recessive mutations in the GAA gene, leading to deficiency of the acid alpha-glucosidase enzyme and subsequent lysosomal glycogen accumulation, predominantly affecting skeletal and cardiac muscles. Over 300 GAA mutations have been identified, resulting in a broad clinical spectrum ranging from severe cardiac involvement to progressive skeletal muscle weakness. The disease is classified into infantile-onset Pompe disease (IOPD), first described by Johannes Pompe in the 1930s, and late-onset Pompe disease (LOPD), and characterized later by Andrew Engel in 1969. IOPD is marked by profound enzyme deficiency, hypertrophic cardiomyopathy, hypotonia, and respiratory failure, often leading to death within the first year if untreated, whereas LOPD arises from partial enzyme deficiency and typically presents with slowly progressive, symmetric limb-girdle muscle weakness that may begin anytime from infancy to adulthood. The phenotypic severity is primarily determined by the extent of residual GAA enzyme activity.
Pompe disease is caused by deficiency of the acid alpha-glucosidase (GAA) enzyme, which normally degrades glycogen into glucose within lysosomes across various tissues. Impaired GAA activity leads to excessive glycogen accumulation and progressive enlargement of lysosomes, predominantly affecting skeletal and cardiac muscles. The resulting cellular damage is driven primarily by lysosomal rupture and disrupted autophagy. Autophagy, a critical cellular recycling process responsible for energy balance and clearance of damaged proteins and intracellular debris, becomes dysfunctional in Pompe disease, leading to accumulation of autophagosomes. This autophagic buildup, together with rupture of glycogen-laden lysosomes and release of their contents into the sarcoplasm, contributes significantly to muscle dysfunction and progressive tissue injury.

Pompe disease is definitively diagnosed through enzyme assays and genetic testing, while clinical evaluation, muscle enzyme analysis, and electromyography (EMG) guide initial suspicion, particularly in late-onset Pompe disease (LOPD). LOPD typically presents with slowly progressive limb-girdle muscle weakness, frequently accompanied by respiratory insufficiency, postural abnormalities such as lumbar lordosis or camptocormia, scapular winging, and predominant weakness of the thigh adductors. Creatine kinase (CK) levels are usually mildly to moderately elevated, and EMG commonly demonstrates irritable myopathy with characteristic myotonic discharges in the paraspinal muscles. Definitive investigations include muscle biopsy revealing glycogen-filled vacuolated fibers, enzyme assays confirming acid alpha-glucosidase deficiency in tissue or blood-based samples, and GAA gene sequencing to identify pathogenic mutations. Due to its rarity and slow progression, LOPD often experiences a diagnostic delay of over a decade, whereas infantile-onset Pompe disease (IOPD) is increasingly identified early through newborn screening programs that utilize blood spot enzyme assays followed by confirmatory genetic testing and clinical evaluation.

Management of Pompe disease involves a multidisciplinary approach combining supportive care with disease-modifying therapies. Comprehensive care includes coordinated management by neurology, pulmonology, cardiology, rehabilitation, respiratory therapy, nutrition, and genetics teams to address progressive muscle weakness, respiratory insufficiency, and systemic complications. Regular aerobic exercise and pulmonary monitoring are essential, with non-invasive ventilation improving survival and quality of life in patients with respiratory involvement. Enzyme replacement therapy (ERT) with recombinant acid alpha-glucosidase remains the cornerstone of treatment, significantly improving survival, cardiac function, mobility, and respiratory outcomes, particularly when initiated early. Newer ERT formulations have been developed to enhance cellular uptake and therapeutic efficacy, although long-term benefits remain under evaluation. Emerging therapies, including gene therapy, substrate reduction strategies, and antisense approaches, aim to provide sustained enzyme production and more durable disease control, offering promising future directions for Pompe disease management.
"Pompe Disease- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pompe Disease pipeline landscape is provided which includes the disease overview and Pompe Disease treatment guidelines. The assessment part of the report embraces, in depth Pompe Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pompe Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Pompe Disease Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pompe Disease R&D. The therapies under development are focused on novel approaches to treat/improve Pompe Disease.

Pompe Disease Emerging Drugs Analysis

This segment of the Pompe Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pompe Disease Emerging Drugs

S-606001: Shionogi & Co., Ltd.

S-606001 is an investigational substrate reduction therapy (SRT) designed to reduce glycogen accumulation within muscle lysosomes by inhibiting glycogen synthase (GYS1). Unlike enzyme replacement therapy (ERT), which enhances glycogen breakdown through supplementation of the GAA enzyme, S-606001 aims to slow glycogen production and accumulation at its source. By targeting a complementary pathway to ERT, this therapeutic approach has the potential to be effective both as a standalone treatment and in combination with ERT for Pompe disease. Currently, the drug is in Phase II stage of its development for the treatment of Late Onset of Pompe Disease.

AT845: Astellas Gene Therapies

AT845 is an investigational adeno-associated virus serotype 8 (AAV8)-based gene therapy carrying the full-length human acid alpha-glucosidase (hGAA) gene under the control of cardiac and skeletal muscle-specific creatine kinase promoters. By enabling targeted GAA expression directly within muscle tissue, AT845 is designed to address a major limitation of enzyme replacement therapy (ERT), namely inadequate restoration of GAA activity in skeletal and cardiac muscles. According to company’s pipeline, the drug is in Phase II stage of its development for the treatment of Pompe Disease.

AB1009: Bayer AG/Ask Bio

AB-1009 is an investigational adeno-associated virus (AAV)-based gene therapy being developed for Pompe disease, particularly late-onset Pompe disease (LOPD). It is designed to address the underlying genetic defect by enabling sustained production of acid alpha-glucosidase (GAA), the enzyme deficient in affected individuals, with the goal of improving long-term disease management. The program has also benefited from early scientific contributions from Genethon, Belief BioMed, and Duke University. According to company’s pipeline, the drug is in Phase I/II stage of its development for the treatment of Pompe Disease.

DNL952: Denali Therapeutics Inc.

DNL952 (ETV:GAA) is an investigational therapy being developed by Denali. This treatment is proposed to work by using the Enzyme TransportVehicle™ (ETV) to enhance delivery of the missing enzyme, GAA, into muscle tissues and across the blood-brain barrier into the brain. Denali is conducting a Phase I clinical study of DNL952 in participants with late-onset Pompe disease.

Further product details are provided in the report……..

Pompe Disease Drug Therapeutic Assessment

This segment of the report provides insights about the different Pompe Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Pompe Disease  Players in Pompe Disease

There are approx. 15+ key companies which are developing the therapies for Pompe Disease. The companies which have their Pompe Disease drug candidates in the most advanced stage, i.e. Phase II include, Shionogi & Co., Ltd.

Pompe Disease Clinical Trial Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Pompe Disease Drug Route of Administration

Pompe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Pompe Disease Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
  Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Pompe Disease Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pompe Disease Clinical Trial Activities 

The Pompe Disease Pipeline report provides insights into different Pompe Disease Clinical Trials within Phase III, II, I, preclinical and discovery stage. It also analyses Pompe Disease therapeutic drugs key players involved in developing key drugs. 

Pompe Disease Pipeline Development Activities

The Pompe Disease Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pompe Disease drugs.

Pompe Disease Pipeline Report Insights

• Pompe Disease Pipeline Analysis
• Pompe Disease Therapeutic Assessment
• Pompe Disease Unmet Needs
• Impact of Pompe Disease Drugs

Pompe Disease Pipeline Report Assessment

• Pompe Disease Pipeline Product Profiles
• Pompe Disease Therapeutic Assessment
• Pompe Disease Pipeline Assessment
• Pompe Disease Inactive drugs assessment
• Pompe Disease Unmet Needs

Key Questions Answered in the Pompe Disease Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Pompe Disease drugs?
• How many Pompe Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pompe Disease?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pompe Disease therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Pompe Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Pompe Disease Key Players

• Shionogi & Co., Ltd.
• Astellas Gene Therapies
• Bayer AG
• Ask Bio
• Denali Therapeutics Inc.
• Gene Cradle Therapeutics
• Aro Biotherapeutics
• Genethon
• M6P Therapeutics
• Dyne Therapeutics
• Fortress Biotech
• AVROBIO

Pompe Disease Key Products

• S-606001
• AT845
• AB1009
• ACTUS-101
• DNL952
• GC301
• ABX1100
• Research Program: Pompe Disease
• M021
• DYNE-401
• ATX-04
• AVR-RD-03